Biomerica, Inc. revenue by segment BMRA

Annual Quarterly

Biomerica, Inc. splits its revenue into 4 lines in its filings. The largest line in Q1 of fiscal 2027, the quarter ended Aug 31, 2026 was Clinical Lab at $775,000, 61% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Aug 31, 2026	Q1 FY2027 Aug 31, 2026	Q4 FY2026 May 31, 2026	Q3 FY2026 Feb 28, 2026	Q2 FY2026 Nov 30, 2025	Q1 FY2026 Aug 31, 2025	Q4 FY2025 May 31, 2025	Q3 FY2025 Feb 28, 2025	Q2 FY2025 Nov 30, 2024
Revenue	4	1	1	1	1	1	1	1	2
Clinical Lab	2 -15.2% share 57.2%	1 -24.3% share 61.3%	0 -17.5% share 47.0%	1 -1.0% share 62.9%	1 -13.0% share 55.9%	1 share 74.2%	0 share 66.5%	1 share 56.0%	1 share 47.5%
Over The Counte	1 -7.0% share 21.9%	0 +80.7% share 23.0%	0 +5.2% share 11.7%	0 +15.9% share 20.0%	0 -39.4% share 29.8%	0 share 11.7%	0 share 13.0%	0 share 15.2%	1 share 36.4%
Contract Manufacturing	1 -2.9% share 20.7%	0 +2.6% share 15.6%	0 +139.3% share 41.0%	0 -47.8% share 16.9%	0 -33.8% share 14.2%	0 share 13.9%	0 share 20.0%	0 share 28.6%	0 share 15.9%
Physicians Office	0 -27.3% share 0.2%	0 -33.3% share 0.2%	0 -25.0% share 0.3%	0 +0.0% share 0.2%	0 -66.7% share 0.1%	0 share 0.2%	0 share 0.5%	0 share 0.2%	0 share 0.2%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as: BMRA (Nasdaq)
Fiscal year ends: May 31
Incorporated in: DE
Headquarters: Irvine, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 73290

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.